Physician profile
Robert A Harris
NPI 1174566053
$616.14
in general payments reported to CMS, 2019-2025
13 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2024: $342 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.96 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $150.00 | 2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $124.18 | 2019 | |
| Lilly USA, LLC | $53.82 | 2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $44.37 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $41.69 | 2024 | Otezla, Repatha, Prolia |
| E.R. Squibb & Sons, L.L.C. | $40.26 | 2024 | Eliquis |
| Pfizer INC. | $39.61 | 2024 | |
| Astellas Pharma US INC | $37.56 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $20.68 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $18.56 | 2024 | Wegovy |
| Paratek Pharmaceuticals, INC. | $15.87 | 2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $15.20 | 2024 | |
| Exact Sciences Corporation | $14.34 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.